Quick answer
How is NAD+ studied in neuronal injury and neurodegeneration models? Mostly through axon degeneration and DNA-repair-deficiency systems. Published work reported that increased Nmnat activity spares axons through SIRT1 (Araki et al., 2004), that SARM1 triggers local axon degeneration by rapidly breaking down NAD+ (Gerdts et al., 2015) because its TIR domain has intrinsic NAD+-cleaving activity (Essuman et al., 2017), that NAD+/SIRT1 reduction contributes to defective mitophagy in an XPA repair-deficiency model (Fang et al., 2014), and that nicotinamide riboside normalized NAD+/NADH and several pathologies in a DNA-repair-deficient Alzheimer mouse model (Hou et al., 2018). This page lays out those model systems, their readouts and the controls. For laboratory research use only; see the NAD+ 1000 mg product page and NAD+ research overview.
Neuronal models give NAD+ research some of its clearest experiments, because axons make the supply and consumption of NAD+ unusually visible: when NAD+ falls, axons fail. This article walks through the main model families in the preclinical literature, what each measures, and the design choices that make a result interpretable. It reports published mouse and cell findings as findings, and it does not suggest any use of the compound outside a laboratory. The material is supplied for laboratory research use only; not for human consumption.
Axon degeneration as an NAD+ experiment
Axon degeneration is described as an active program of self-destruction seen in many physiological and pathological settings. In Wallerian degeneration slow (wlds) mice, degeneration after axonal injury is delayed because of a mutation producing a chimeric protein of Ufd2a and the NAD biosynthetic enzyme Nmnat1. Araki and colleagues demonstrated that increased Nmnat activity is responsible for the axon-sparing activity of the Wlds protein, and that SIRT1, the mammalian ortholog of Sir2, is the downstream effector of increased Nmnat activity leading to axonal protection (Araki et al., 2004). The experiment is a clean NAD+ supply manipulation with a morphological readout.
The model also shows a basic logic worth copying: a defined injury (transection or toxin), a defined manipulation of NAD+ supply (Nmnat expression), a dependence test (SIRT1), and a quantitative axon-integrity readout. The supply side is explained in our NAD+ research overview and in the pathway article on NAD+ biosynthesis routes published in this series.
SARM1: NAD+ destruction as the executioner
Gerdts and colleagues reported that SARM1 (sterile alpha and TIR motif-containing 1) is an essential mediator of axon degeneration, initiating a local destruction program involving rapid breakdown of NAD+ after injury. An engineered protease-sensitized SARM1 showed that SARM1 activity is required after axon injury, dimerization of its TIR domain alone was sufficient to induce locally mediated axon degeneration, and the dimer triggered rapid NAD+ breakdown, whereas SARM1-induced axon destruction could be counteracted by increased NAD+ synthesis. They proposed that SARM1-induced depletion of NAD+ may explain the potent axon protection in Wlds mutant mice (Gerdts et al., 2015).
Essuman and colleagues then identified the NAD+-depleting activity. Using purified proteins and cell-free systems, they showed that the SARM1-TIR domain itself has intrinsic NADase activity, cleaving NAD+ into ADP-ribose, cyclic ADP-ribose and nicotinamide, with nicotinamide acting as a feedback inhibitor. In neurons with traumatic and vincristine-induced injury, the NADase activity of full-length SARM1 was required in axons for NAD+ depletion and axonal degeneration after injury (Essuman et al., 2017).
For experimental design, the SARM1 work changes the question from does NAD+ supply matter to is NAD+ consumption by SARM1 the limiting event. The table summarizes how the pieces fit.
| Component | Role reported | Readout | Source |
|---|---|---|---|
| Nmnat (Wlds fusion) | Increased NAD synthesis spares axons | Axon integrity after injury | Araki et al., 2004 |
| SIRT1 | Downstream effector of Nmnat protection | Axon integrity with SIRT1 activation or loss | Araki et al., 2004 |
| SARM1 TIR dimerization | Sufficient to induce local degeneration | Axon fragmentation; NAD+ level | Gerdts et al., 2015 |
| SARM1 enzymatic activity | Intrinsic NADase producing ADPR, cADPR, nicotinamide | In-vitro NAD+ cleavage; axonal NAD+ | Essuman et al., 2017 |
| Increased NAD+ synthesis | Counteracts SARM1-induced destruction | Axon survival | Gerdts et al., 2015 |
DNA-repair-deficiency models and mitophagy
A second family links NAD+ to DNA damage and mitochondrial quality control. Fang and colleagues identified mitochondrial dysfunction in xeroderma pigmentosum group A (XPA), a nucleotide excision DNA repair disorder with severe neurodegeneration. XPA-deficient cells showed defective mitophagy with excessive cleavage of PINK1 and increased mitochondrial membrane potential, which appeared to be caused by decreased activation of the NAD+-SIRT1-PGC-1alpha axis triggered by hyperactivation of the DNA damage sensor PARP-1. The phenotype was rescued by PARP-1 inhibition or by supplementation with NAD+ precursors, which also rescued the lifespan defect in xpa-1 nematodes, and the pathogenesis appeared common to two other repair disorders with neurodegeneration but absent in XPC, a repair disorder without neurodegeneration (Fang et al., 2014).
The design logic is a competition for a shared pool: PARP-1 consumes NAD+ when DNA damage is high, which leaves less for SIRT1. The matching controls are PARP-1 inhibition (to preserve NAD+), precursor supply (to raise it), and a repair-deficient line without the neurodegenerative phenotype (XPC in the paper) to test specificity.
A mouse model of Alzheimer-type pathology with DNA-repair deficiency
Hou and colleagues developed a DNA-repair-deficient 3xTgAD/Polbeta+/- mouse that exacerbates major features of human Alzheimer's disease, including phosphorylated Tau pathologies, synaptic dysfunction, neuronal death and cognitive impairment. They reported a reduced cerebral NAD+/NADH ratio, indicating impaired cerebral energy metabolism, which was normalized by nicotinamide riboside. NR lessened pTau pathology but had no impact on amyloid-beta accumulation; NR-exposed double-mutant mice showed reduced DNA damage, neuroinflammation and hippocampal neuron apoptosis, with increased brain SIRT3 activity, and NR improved performance in behavioral tests and restored hippocampal synaptic plasticity (Hou et al., 2018). The authors interpret this as a role for NAD+ depletion upstream of several pathologies.
As a design template this study is valuable for its multi-level readouts (metabolite ratio, pathology markers, DNA damage, electrophysiology, behavior) and its genotype comparison. As a source of conclusions it is limited to the mouse models used: the findings do not imply that any use outside laboratory research is appropriate, and the paper's own closing statement about interventions is the authors' interpretation, not a claim made on this page. A further limit is that three of the four model families here involve genetic lesions that are severe by design; they are built to make a pathway visible, which is exactly why a result in them should be read as evidence about the pathway and not about any general state of the nervous system.
Choosing a model and building controls
The four model families answer different questions. Choosing between them starts with the level of the hypothesis.
| Hypothesis level | Model | Primary readout | Essential controls |
|---|---|---|---|
| NAD+ supply protects axons | Cultured neurons or explants with injury | Axon integrity score or fragmentation index | Vehicle; enzyme-dead Nmnat; SIRT1 perturbation |
| NAD+ consumption drives axon loss | SARM1 wild-type vs knockout or catalytically dead neurons | Axonal NAD+; fragmentation | Nicotinamide as feedback inhibitor control; injury-matched vehicle |
| PARP-1 competes with sirtuins for NAD+ | DNA-repair-deficient cells or worms | Mitophagy markers; membrane potential; lifespan | PARP-1 inhibition; non-neurodegenerative repair mutant |
| NAD+ depletion is upstream of pathology | Transgenic mouse with repair deficiency | NAD+/NADH ratio; pTau; synaptic and behavioral tests | Genotype and exposure groups; blinded scoring |
Across all of them: measure NAD+ directly rather than assuming it changed; use blinded, quantitative axon or pathology scoring; separate acute injury readouts from slow ones; and report group sizes, sex and age for animal work. The standard cautions on delivery of NAD+ apply: because extracellular NAD+ is degraded to permeable precursors before cell entry (Nikiforov et al., 2011), cultured-neuron experiments that add NAD+ to the medium should include precursor comparisons and measure intracellular levels.
Material handling and documentation
The NAD+ 1000 mg product page lists a 1000 mg lyophilized powder, formula C21H27N7O14P2, stated purity of at least 98%, stored at 2–8 °C or −20 °C long term and protected from heat, moisture and light. A COA is marked as coming soon; confirm on the page before relying on documentation, and see the COA page and NAD+ purity testing. Calculate stock concentrations with the molar mass and the calculator, record the time between preparation and use, and file the lot number with the study record. For related reading see NAD+ research applications, NAD+ versus NMN versus NR and the shop.
Frequently asked questions
What did the Wlds mouse studies show about NAD?
Increased Nmnat activity is responsible for the axon-sparing activity of Wlds protein, with SIRT1 as the downstream effector (Araki et al., 2004).
What is SARM1?
A protein described as an essential mediator of axon degeneration that initiates a local program of rapid NAD+ breakdown after injury (Gerdts et al., 2015).
Does SARM1 break down NAD+ itself?
Yes, the TIR domain has intrinsic NADase activity, cleaving NAD+ to ADP-ribose, cyclic ADP-ribose and nicotinamide (Essuman et al., 2017).
What inhibits SARM1's NADase feedback?
Nicotinamide, which serves as a feedback inhibitor in the purified-protein experiments.
How does PARP-1 connect to NAD+?
In XPA-deficient models, hyperactivation of PARP-1 was linked to reduced NAD+-SIRT1 signaling and defective mitophagy (Fang et al., 2014).
What was rescued in the XPA study?
The mitochondrial phenotype by PARP-1 inhibition or NAD+ precursors, and the lifespan defect in nematodes.
What did NR do in the 3xTgAD/Polbeta+/- mice?
It normalized the cerebral NAD+/NADH ratio and lessened pTau pathology without affecting amyloid-beta accumulation (Hou et al., 2018).
What readouts do these models share?
Direct NAD+ measurement, a quantitative structural or pathology score, and a dependence test for the proposed mediator.
Can these results be applied outside the models?
The abstracts report mouse, nematode and cell findings; extending them is outside what the studies establish.
What does the product page state about NAD+?
A 1000 mg lyophilized powder with formula C21H27N7O14P2, stored at 2–8 °C or −20 °C long term, with a COA marked as coming soon.
Responsible research use
Everything on this page is offered for laboratory research use only; it is background reading for qualified researchers, not guidance for any use outside a research setting, and nothing here is a claim about benefit in people or animals. Products from V8 Peptides are sold strictly as research materials: not a drug, food or cosmetic, and not for human or animal consumption. Published studies described here were run by their authors under their own approvals and protocols, and this page does not recommend repeating them.
Related reading: NAD+ Structure and Function: A Molecular Research Guide, NAD+ Stability: Degradation Chemistry and QC Checks, Comparing NAD+ Suppliers: A Lab Sourcing Framework.
References
- Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305(5686):1010-1013. doi:10.1126/science.1098014
- Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD+ destruction. Science. 2015;348(6233):453-457. doi:10.1126/science.1258366
- Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron. 2017;93(6):1334-1343.e5. doi:10.1016/j.neuron.2017.02.022
- Fang EF, Scheibye-Knudsen M, Brace LE, Kassahun H, SenGupta T, Nilsen H, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. Cell. 2014;157(4):882-896. doi:10.1016/j.cell.2014.03.026
- Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, et al. NAD+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018;115(8):E1876-E1885. doi:10.1073/pnas.1718819115
- Nikiforov A, Dölle C, Niere M, Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem. 2011;286(24):21767-21778. doi:10.1074/jbc.M110.213298
